Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects

NCT03082937 is registered in ClinicalTrials.gov with Albireo as lead sponsor.

NCT NCT03082937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03082937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects
Lead sponsor
Albireo
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2017
Completion date
March 8, 2017
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alagille syndrome, orphan cholestatic liver diseases, primary biliary cirrhosis, progressive familial intrahepatic cholestasis